Cancer Screening Guidelines

Mechanistic groupings

• Infectious/viral carcinogenesis: High-risk HPV 16/18 integrates E6/E7, inactivating p53 and Rb → cervical dysplasia; chronic HBV/HCV and cirrhosis drive hepatocellular carcinoma, for which AASLD recommends ultrasound surveillance (± AFP) every 6 months rather than any general-population test
• Chemical carcinogens: Tobacco polycyclic aromatic hydrocarbons and nitrosamines cause field cancerization of airway epithelium — the entire basis for USPSTF low-dose CT eligibility by pack-years and years since quitting
• Chronic inflammation: Longstanding ulcerative colitis or Crohn colitis produces dysplasia without a discrete polyp; gastroenterology societies begin surveillance colonoscopy roughly 8 years after colitis onset, at shorter intervals than average-risk screening
• Hormonal drive: Cumulative unopposed estrogen exposure (early menarche, late menopause, nulliparity, menopausal hormone therapy) raises breast cancer risk
• Germline mutation: BRCA1/2, Lynch syndrome (MMR genes), and FAP (APC) collapse the multi-step mutation timeline; NCCN moves these patients to earlier, more frequent, more sensitive testing (e.g., annual breast MRI plus mammography in BRCA carriers; colonoscopy beginning in the third decade in Lynch syndrome)
• Prior therapeutic radiation: Chest irradiation for Hodgkin lymphoma in adolescence/young adulthood — ACS advises adding breast MRI years after exposure

Non-modifiable risk factors examiners plant

• Age: the single strongest determinant, and the axis on which every USPSTF recommendation is written
• Family history: a first-degree relative with colorectal cancer or advanced adenoma prompts starting colonoscopy earlier than the average-risk age
• Ancestry/race: Ashkenazi Jewish founder BRCA mutations; Black men carry higher prostate cancer incidence and mortality, which NCCN cites for beginning the shared decision-making discussion earlier
• Sex, prior cancer, prior high-grade dysplasia

Modifiable risk factors

• Smoking, alcohol, obesity and physical inactivity, HPV vaccination status, and immunosuppression (HIV, transplant), which intensifies cervical screening rather than relaxing it

• Multi-step carcinogenesis: Most cancers develop through accumulation of genetic mutations over years to decades (adenoma-carcinoma sequence in colorectal cancer, HPV→CIN→cervical cancer), creating an identifiable preclinical phase where detection improves prognosis
• Lead time bias and stage shift: Screening detects cancers at earlier stages when treatment is more effective; survival appears improved even without true mortality benefit if detection simply occurs earlier without changing outcome
• Tumor growth kinetics: Cancers have variable doubling times; slower-growing tumors have longer screening-detectable preclinical phases, making them more suitable for screening programs
• Sensitivity vs. specificity trade-off: Screening tests must balance detecting true disease (sensitivity) against minimizing false positives (specificity), as false positives lead to anxiety and unnecessary interventions

Key principle: Screening by definition targets asymptomatic individuals; symptomatic patients require diagnostic evaluation, not screening. However, screening may detect preclinical abnormalities

• Abnormal screening test results without symptoms: Pap smear showing dysplasia, colonoscopy revealing adenomatous polyp, elevated PSA without urinary symptoms, or mammographic density/microcalcifications are all detected in asymptomatic individuals
• Incidental findings: Screening may identify unsuspected cancers or precancers (e.g., lung nodule on low-dose CT screening for smoking history, incidental renal mass on abdominal imaging)
• Important clinical pearl: Screening tests are not appropriate for patients with cancer symptoms (abnormal vaginal bleeding, hematuria, melena); these patients require diagnostic evaluation with imaging, endoscopy, or biopsy rather than screening tests

• Cervical cancer screening: Pap smear (cytology) every 3 years (age 21-65) OR HPV testing every 5 years OR co-testing (both) every 5 years; abnormal results trigger colposcopy with biopsy for CIN (cervical intraepithelial neoplasia) grading
• Colorectal cancer screening: Colonoscopy every 10 years (gold standard, allows polypectomy), FOBT/FIT annually, flexible sigmoidoscopy every 5 years, or CT colonography every 5 years; age 45-75 (USPSTF 2021 lowered from 50), individualize beyond 75; adenomatous polyps risk-stratify follow-up intervals
• Breast cancer screening: Mammography every 1-2 years (age 40-44 optional, 45-54 annual or biennial, 55+ biennial); MRI for high-risk (BRCA+, >20% lifetime risk); abnormal findings → diagnostic imaging ± biopsy
• Prostate cancer screening: PSA ± digital rectal exam (DRE); shared decision-making emphasized (USPSTF gives "C" recommendation for routine screening); age 55-69 individualized; abnormal PSA → transrectal ultrasound-guided biopsy if clinical suspicion high
• Lung cancer screening: Low-dose CT (LDCT) annually for age 50-80 with ≥20 pack-year smoking history (quit <15 years ago); Lung-RADS criteria guide follow-up of nodules based on size/morphology
• Important diagnostic consideration: Positive predictive value (PPV) of screening tests increases with age and risk factors (screening same-risk population improves PPV)

• Precancerous lesions: Cervical dysplasia (CIN 1-3) managed with observation (mild), loop electrosurgical excision procedure (LEEP) or cold knife conization (moderate-severe), or excisional biopsy with margin assessment; colorectal adenomatous polyps resected at colonoscopy with surveillance intervals based on polyp number/size/histology
• Early-stage cancers detected by screening: Typically localized disease amenable to surgery ± radiation ± chemotherapy depending on cancer type and stage; exact treatment beyond scope of screening guidelines but outcomes superior due to earlier detection
• Follow-up after abnormal screening: Diagnostic confirmation required before treatment initiation; for example, abnormal mammogram requires diagnostic imaging ± biopsy before breast cancer diagnosis confirmed

• False positives leading to unnecessary procedures: Abnormal Pap smear requiring colposcopy (10-15% complication rate including bleeding, perforation if found), benign breast biopsy from mammographic finding, or biopsy for elevated PSA that is not cancer—causes patient anxiety and healthcare costs
• Overdiagnosis and overtreatment: Screening detects indolent cancers/precancers that would never cause clinical harm (e.g., low-grade DCIS of breast, slow-growing prostate cancer in elderly men); patients undergo treatment without mortality benefit, experiencing treatment toxicity unnecessarily
• Procedural complications: Colonoscopy perforation (0.03%), bleeding post-polypectomy (0.3-1%), anesthesia complications; lung biopsy for nodules causing pneumothorax or infection
• Life-threatening complications: Perforated colon during colonoscopy (surgical emergency), sepsis from instrumentation, massive hemorrhage post-procedure (rare but serious)
• Interval cancers: Cancers developing between screening intervals due to test false-negative rate or rapid growth; increases patient distrust in screening

• Screening vs. diagnosis difference: Screening tests target asymptomatic populations; symptomatic patients need diagnostic evaluation—a common USMLE trap is recommending screening to someone with symptoms (e.g., "screen for lung cancer" in patient with hemoptysis = incorrect; needs diagnostic CT/bronchoscopy)

• Age matters critically: Screening recommendations are age-stratified—cervical cancer screening begins at age 21, colorectal age 45-50, breast age 40-55+, prostate age 50-70 with shared decision-making. Starting too young (screening teenagers for cervical cancer) or continuing too old (colonoscopy after age 75-85 in average-risk patients) decreases benefit-to-harm ratio.

• USPSTF grades: A/B recommendations = screening proven beneficial; C grade = individualize (e.g., prostate cancer screening is "C"); D recommendation = do not screen (e.g., routine screening for ovarian cancer). Knowing these grades is high-yield.

• Risk stratification determines screening intensity: High-risk individuals need earlier start ages, shorter intervals, more sensitive tests (e.g., BRCA+ women get breast MRI + mammography; high-grade dysplasia on prior colonoscopy shortens surveillance to 3 months vs. 10 years for normal baseline)

• HPV is the game-changer for cervical cancer: HPV testing is more sensitive than cytology; HPV-negative = low risk even with abnormal cytology; HPV-positive = requires colposcopy. This shifted cervical cancer screening paradigm and is frequently tested.

• Lung cancer screening is LDCT (not chest X-ray): Low-dose CT reduces lung cancer mortality 20% in high-risk smokers (NLST trial); chest X-ray does not reduce mortality and is no longer recommended for screening—